NCT00227513View on ClinicalTrials.gov

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2010

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

bortezomib

Given IV

DRUG

vorinostat

Given orally

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00227513 - Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter